SmartPharm’s goal is to replace recombinant protein therapeutics with gene-encoded therapeutics (GETs). Our company has selected three areas of focus and has initiated product development in each of these areas:
Gene MAbs™: Gene-encoded antibodies for coronavirus COVID-19 (SARS-CoV-2).
Enzyme Replacement Therapy: Initial focus on lysosomal storage diseases.
Preservation and restoration of cell and tissue viability: Prevention of cell or tissue death from medical conditions or interventions.
SmartPharm’s initial focus is on development of a DNA-based neutralizing antibody against the SARS-CoV-2 virus, the coronavirus that causes COVID-19. It is also developing a non-viral enzyme replacement therapy for Gaucher disease type 1, and has developed an mRNA-based treatment to preserve cardiac tissue following acute myocardial infarction, which the company is currently partnering for future development.